RxDoctor Payments Data

Jennifer Chester

Family · Overland Park, KSNPI 1447582721

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $228,155 of the $327,217 with a category attached, or 69.7%. 46 manufacturers reported payments, led by EMD Serono, Inc. at 44.8% of the total. Reporting peaked in 2024 at $93,470 and has fallen 99.6% since, to $387 in 2025. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$327,217in general payments, 2019–2025

Across 1,483 payments — averaging $220.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$147K
  • Biogen$55K
  • AbbVie$41K
  • Sanofi$21K
  • Biohaven Pharmaceuticals, Inc.$14K
  • Biohaven Pharmaceutical Holding Company Ltd.$11K
  • plus $39K from 40 others

What the payments were for

  • Consulting fees$24,7288%
  • Speaking & faculty fees$228,15570%
  • Travel & lodging$43,47113%
  • Food & beverage$29,6049%
  • Education$1,2580%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$327,217 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$498,260
Medicare patients
144
Services billed
21,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4636$191,465
Aimovig AutoinjectorErenumab-Aooe73$53,312
Nurtec OdtRimegepant Sulfate32$45,008
Dalfampridine ErDalfampridine44$10,537
Ajovy AutoinjectorFremanezumab-Vfrm12$8,654
Baclofen112$3,872
Gabapentin85$2,600
Duloxetine Hcl45$2,466
Modafinil35$2,352
RizatriptanRizatriptan Benzoate76$1,537
Lamotrigine22$1,253
Memantine Hcl38$1,145
Oxcarbazepine23$1,102
Tizanidine Hcl52$863
Nortriptyline Hcl48$818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$717$45,00832 claims
Upsher-smith Laboratories LLCTopiramate$83$67042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.

Other family in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →